https://www.clavystbio.com 2026-10-13T10:02:20.601Z https://www.clavystbio.com/about 2026-10-20T03:49:27.290Z https://www.clavystbio.com/portfolio 2026-10-13T07:12:14.013Z https://www.clavystbio.com/team 2026-10-10T03:04:28.177Z https://www.clavystbio.com/board 2026-10-10T03:04:28.177Z https://www.clavystbio.com/news 2026-09-27T02:21:57.039Z https://www.clavystbio.com/in-the-news 2026-09-27T02:21:57.039Z https://www.clavystbio.com/insights 2026-09-27T02:21:57.039Z https://www.clavystbio.com/contact 2026-10-20T03:49:27.442Z https://www.clavystbio.com/portfolio/automera 2026-10-22T06:37:31.575Z https://www.clavystbio.com/portfolio/bisirna-therapeutics 2026-10-20T05:10:16.885Z https://www.clavystbio.com/portfolio/biobot 2026-10-31T02:31:24.096Z https://www.clavystbio.com/portfolio/callio-therapeutics 2026-10-22T06:25:46.026Z https://www.clavystbio.com/portfolio/cirrus-therapeutics 2026-10-20T05:13:25.585Z https://www.clavystbio.com/portfolio/engine-biosciences 2026-10-22T06:26:12.705Z https://www.clavystbio.com/portfolio/eyexora 2026-10-22T06:26:38.625Z https://www.clavystbio.com/portfolio/hummingbird-bioscience 2026-10-22T07:19:40.857Z https://www.clavystbio.com/portfolio/iaso-biotechnology 2026-10-22T06:27:36.570Z https://www.clavystbio.com/portfolio/leyden-labs 2026-10-22T06:27:53.877Z https://www.clavystbio.com/portfolio/nuevocor 2026-10-22T06:28:05.834Z https://www.clavystbio.com/portfolio/paratus-sciences 2026-10-22T06:28:22.094Z https://www.clavystbio.com/portfolio/quilt 2026-10-20T05:22:11.047Z https://www.clavystbio.com/portfolio/rejoni 2026-10-22T07:19:41.072Z https://www.clavystbio.com/portfolio/respiree 2026-10-22T06:28:51.282Z https://www.clavystbio.com/portfolio/zenflow 2026-10-22T07:19:41.264Z https://www.clavystbio.com/portfolio/65lab 2026-10-22T06:29:19.100Z https://www.clavystbio.com/board/alan-thompson 2026-10-26T03:31:58.155Z https://www.clavystbio.com/board/wu-yibing 2026-10-26T03:45:36.206Z https://www.clavystbio.com/board/ethan-park 2026-10-26T03:45:40.860Z https://www.clavystbio.com/board/ken-ehlert 2026-10-26T03:45:52.367Z https://www.clavystbio.com/team/khoo-shih 2026-10-22T06:48:05.807Z https://www.clavystbio.com/team/kang-lin-ong 2026-10-22T06:47:40.759Z https://www.clavystbio.com/team/anselm-tan 2026-10-22T06:47:25.436Z https://www.clavystbio.com/team/charles-zhang 2026-10-22T06:45:05.795Z https://www.clavystbio.com/team/cheryl-tan 2026-10-22T06:49:49.946Z https://www.clavystbio.com/team/jamie-wong 2026-10-22T06:47:01.363Z https://www.clavystbio.com/team/jason-ng 2026-10-22T06:46:17.555Z https://www.clavystbio.com/team/johnny-ng 2026-10-22T06:50:28.175Z https://www.clavystbio.com/team/marcus-tan 2026-10-22T07:00:09.080Z https://www.clavystbio.com/team/ning-mao 2026-10-22T06:49:17.251Z https://www.clavystbio.com/team/nge-hwee-ng 2026-10-20T03:49:30.115Z https://www.clavystbio.com/team/yingmin-wang 2026-10-22T06:51:31.979Z https://www.clavystbio.com/team/yvonne-koh 2026-10-22T06:52:00.414Z https://www.clavystbio.com/team/wen-qi-ho 2026-10-22T06:45:35.664Z https://www.clavystbio.com/board/ranga-krishnan 2026-10-26T03:46:00.375Z https://www.clavystbio.com/board/steve-krognes 2026-10-26T03:46:11.094Z https://www.clavystbio.com/board/vicki-sato 2026-10-26T03:46:05.240Z https://www.clavystbio.com/board/andreas-wallnofer 2026-10-26T03:46:15.799Z https://www.clavystbio.com/board/andrew-cleeland 2026-10-26T03:46:24.666Z https://www.clavystbio.com/board/sean-marett 2026-10-26T03:46:20.287Z https://www.clavystbio.com/insights/clavystbio-conversations-with-robert-abraham 2026-10-21T02:50:42.120Z https://www.clavystbio.com/insights/industry-insight-article-fundraising-101-milestones-and-money-how-life-sciences-rounds-get-staged 2026-10-31T02:52:46.547Z https://www.clavystbio.com/insights/clavystbio-building-global-health-impact 2026-09-27T22:25:20.943Z https://www.clavystbio.com/insights/fireside-chat-with-lilly-ventures- 2026-10-21T02:59:17.607Z https://www.clavystbio.com/insights/building-bsl2-lab-singapore-costs 2026-10-31T02:52:39.962Z https://www.clavystbio.com/insights/clavystbio-conversation-future-of-clinical-trials 2026-10-21T07:17:09.859Z https://www.clavystbio.com/insights/biotech-deal-dynamics 2026-09-27T22:25:45.770Z https://www.clavystbio.com/insights/clavystbio-portfolio-day-2024 2026-10-21T07:05:57.225Z https://www.clavystbio.com/insights/clavystbio-conversations-with-msd-discovery 2026-09-27T22:25:46.217Z https://www.clavystbio.com/insights/clavystbio-conversations-biotech-venture-building 2026-10-20T06:24:50.506Z https://www.clavystbio.com/insights/clavystbio-conversations-fostering-venture-creation 2026-09-27T22:25:47.305Z https://www.clavystbio.com/insights/-node-1-opening--keynote-panel- 2026-10-21T07:04:01.859Z https://www.clavystbio.com/press-releases/singapore-venture-creation-group-65lab-awards-us169-million-to-astar-led-project-targeting-the-cause-of-vision-loss-in-glaucoma-and-naion 2026-10-22T03:21:43.843Z https://www.clavystbio.com/press-releases/nuevocor-doses-first-patient-in-sunbeam-lmna-phase-12-trial-and-receives-fda-fast-track-designation-for-nvc-001-in-lmna-dilated-cardiomyopathy 2026-10-22T03:20:07.987Z https://www.clavystbio.com/press-releases/zenflow-secures-52m-series-d-financing-and-announces-exclusive-us-distribution-partnership-with-cook-medical 2026-10-22T03:20:24.550Z https://www.clavystbio.com/press-releases/hummingbird-bioscience-announces-first-patient-dosed-in-phase-ii-trial-of-hmbd-001-and-cetuximab-in-advanced-squamous-cell-cancers 2026-10-22T03:20:57.080Z https://www.clavystbio.com/press-releases/rejoni-receives-fda-approval-of-the-juveena-hydrogel-system-to-reduce-intrauterine-adhesions-following-hysteroscopic-adhesiolysis 2026-10-22T03:22:02.790Z https://www.clavystbio.com/press-releases/respiree-extends-series-a-syndicate-with-addition-of-international-investors-to-support-continued-global-growth 2026-10-22T03:22:46.551Z https://www.clavystbio.com/press-releases/hummingbird-bioscience-appoints-dr-james-garner-as-president 2026-10-22T03:23:13.017Z https://www.clavystbio.com/press-releases/callio-therapeutics-appoints-zachary-hornby-as-chief-executive-officer 2026-10-22T03:23:27.807Z https://www.clavystbio.com/press-releases/leyden-labs-reports-positive-phase-1-results-for-rig-101-supporting-advancement-into-phase-2-to-protect-asthma-patients 2026-10-22T03:23:57.128Z https://www.clavystbio.com/press-releases/paratus-sciences-announces-updates-to-its-board-of-directors 2026-10-22T03:24:59.063Z https://www.clavystbio.com/press-releases/iaso-biotechnology-announces-acquisition-of-singapore-based-cell-therapy-company-medisix-therapeutics 2026-10-22T04:57:38.733Z https://www.clavystbio.com/press-releases/cirrus-therapeutics-strengthens-its-position-as-a-next-generation-global-ocular-immunology-leader-with-singapore-eye-research-institute-seri-collaboration-and-additional-financing 2026-10-22T04:58:39.099Z https://www.clavystbio.com/press-releases/biobot-surgical-raises-20-million-led-by-clavystbio-and-supported-by-zig-ventures 2026-10-22T05:00:17.741Z https://www.clavystbio.com/press-releases/globally-recognized-impact-investors-back-leyden-labs-mission-to-transform-protection-against-respiratory-viruses-with-40-million-investment 2026-10-22T05:02:27.462Z https://www.clavystbio.com/press-releases/respiree-appoints-patty-riskind-as-chair-of-the-board-of-directors 2026-10-22T05:03:16.895Z https://www.clavystbio.com/press-releases/singapore-venture-creation-group-65lab-funds-novel-biologics-project-from-national-university-of-singapore-targeting-lung-diseases 2026-10-22T05:04:30.218Z https://www.clavystbio.com/press-releases/rejoni-inc-secures-25-million-in-financing-to-accelerate-the-juveena-hydrogel-system-toward-fda-approval-and-launch 2026-10-22T05:04:45.081Z https://www.clavystbio.com/press-releases/nuevocor-appoints-dr-monica-shah-as-chief-medical-officer 2026-10-22T05:05:46.785Z https://www.clavystbio.com/press-releases/paratus-appoints-alicia-secor-as-president-and-chief-executive-officer-expands-leadership-team-to-support-next-phase-of-growth 2026-10-22T05:06:16.814Z https://www.clavystbio.com/press-releases/callio-therapeutics-doses-first-patient-in-phase-i-clinical-trial-of-dual-payload-adc-clio-8221-in-advanced-her2-expressing-solid-tumors 2026-10-22T05:06:26.449Z https://www.clavystbio.com/press-releases/cirrus-therapeutics-announces-strategic-expansion-to-singapore-and-other-key-updates-supporting-its-growth-as-a-leading-global-ocular-immunology-company 2026-10-22T05:12:09.946Z https://www.clavystbio.com/press-releases/leyden-labs-demonstrates-feasibility-of-novel-antibody-based-nasal-spray-for-flu-prevention 2026-10-22T05:08:51.237Z https://www.clavystbio.com/press-releases/nuevocor-appoints-al-gianchetti-as-chief-executive-officer 2026-10-22T05:09:34.666Z https://www.clavystbio.com/press-releases/biosparc-first-zone-main-structure-completed 2026-10-22T05:10:03.578Z https://www.clavystbio.com/press-releases/eyexora-establishes-co-headquarters-in-singapore-to-accelerate-growth-across-asia-pacific 2026-10-22T05:10:22.613Z https://www.clavystbio.com/press-releases/leyden-labs-secures-30-million-from-european-innovation-council-fund-and-invest-nl-to-advance-nasal-spray-against-respiratory-viruses 2026-10-22T05:11:03.712Z https://www.clavystbio.com/press-releases/cirrus-therapeutics-raises-11-m-seed-financing-to-advance-novel-ocular-gene-therapy-to-reverse-underlying-age-related-cause-of-dry-amd 2026-10-22T05:11:16.165Z https://www.clavystbio.com/press-releases/eyexora-launches-the-first-hub-and-spoke-model-for-accelerating-ophthalmology-innovation 2026-10-22T05:11:25.800Z https://www.clavystbio.com/press-releases/65lab-awards-us-1-5-million-to-duke-nus-platform-to-advance-antifibrotic-drug-discovery 2026-10-22T05:11:35.753Z https://www.clavystbio.com/press-releases/respiree-closes-us-11-6m-series-a-financing-round-led-by-we-venture-capital-and-clavystbio 2026-10-22T05:11:50.814Z https://www.clavystbio.com/press-releases/nuevocor-strengthens-board-with-appointment-of-thierry-abribat 2026-10-22T05:12:39.840Z https://www.clavystbio.com/press-releases/nuevocor-announces-fda-clearance-of-ind-for-nvc-001-for-lmna-related-dilated-cardiomyopathy 2026-10-22T05:12:53.294Z https://www.clavystbio.com/press-releases/clavystbio-and-astar-partner-to-grow-medtech-ventures-in-singapore 2026-10-22T05:13:40.724Z https://www.clavystbio.com/press-releases/callio-therapeutics-launches-with-us-187-million-series-a-to-advance-multi-payload-antibody-drug-conjugate-platform-through-clinical-proof-of-concept-2 2026-10-22T05:15:01.202Z https://www.clavystbio.com/press-releases/cov-biotechnology-takes-next-step-to-become-leyden-labs-asia-advancing-its-mission-to-combat-respiratory-infectious-diseases-2 2026-10-22T05:15:13.215Z https://www.clavystbio.com/press-releases/leyden-labs-raises-70m-to-advance-its-intranasal-antibody-programs-to-protect-against-influenza-and-other-viruses-2 2026-10-22T05:16:36.599Z https://www.clavystbio.com/press-releases/engine-biosciences-secures-27-million-series-a-extension-to-advance-development-of-precision-oncology-medicines-and-novel-biomarkers-for-patient-selection 2026-10-22T05:16:58.420Z https://www.clavystbio.com/press-releases/hummingbird-bioscience-announces-positive-phase-i-clinical-data-for-hmbd-001-monotherapy-trial-at-the-european-society-for-medical-oncology-congress-2023 2026-10-22T05:18:22.106Z https://www.clavystbio.com/press-releases/endeavor-biomedicines-enters-license-agreement-with-hummingbird-bioscience-for-worldwide-rights-to-hmbd-501-a-next-generation-her3-targeted-antibody-drug-conjugate-adc 2026-10-22T05:18:33.883Z https://www.clavystbio.com/press-releases/65lab-launches-in-partnership-with-evotec-se-and-backed-by-leading-global-investors-to-advance-drug-discovery-and-new-company-creation-in-singapore-2 2026-10-22T05:18:44.898Z https://www.clavystbio.com/press-releases/clavystbio-launches-node-1-to-bring-together-life-sciences-communities-to-catalyse-global-human-health-solutions 2026-10-22T05:19:04.513Z https://www.clavystbio.com/press-releases/accelerator-life-science-partners-launches-biotechnology-startup-company-in-singapore-with-16m-in-series-a-commitments-2 2026-10-22T05:19:19.797Z https://www.clavystbio.com/press-releases/paratus-sciences-launches-with-100m-series-a-financing-to-develop-novel-therapeutics-based-on-the-unique-biology-of-bats-2 2026-10-22T05:19:31.388Z https://www.clavystbio.com/privacy 2026-09-29T01:47:07.518Z